Evoke Pharma Inc Form 3 December 18, 2015

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**SECURITIES** 

response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Shah Nimesh

(Last) (First) (Middle)

Statement

(Month/Day/Year)

01/01/2015

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Evoke Pharma Inc [EVOK]

Person(s) to Issuer

4. Relationship of Reporting 5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O DOMAIN ASSOCIATES. LLC, ONE PALMER **SQUARE** 

(Street)

\_X\_ 10% Owner Director

Officer Other (give title below) (specify below)

(Check all applicable)

6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

PRINCETON. NJÂ 08542

(City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

Beneficially Owned

(Instr. 4)

2. Amount of Securities

3. Ownership Form:

4. Nature of Indirect Beneficial Ownership

Direct (D) or Indirect (I)

(Instr. 5)

(Instr. 5)

Common Stock

 $5,250^{(1)}$ 

Ι By Domain Associates, LLC (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1473 (7-02)

4.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

**Expiration Date** (Month/Day/Year)

2. Date Exercisable and 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

5. Conversion or Exercise

Ownership Form of (Instr. 5)

6. Nature of Indirect Beneficial Ownership

Price of Derivative Derivative Security:

1

## Edgar Filing: Evoke Pharma Inc - Form 3

Date Expiration Title Exercisable Date

Amount or Security Number of

Shares

Direct (D) or Indirect (I) (Instr. 5)

**Reporting Owners** 

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Shah Nimesh

C/O DOMAIN ASSOCIATES, LLC ONE PALMER SQUARE PRINCETON, NJÂ 08542

Â X Â Â

**Signatures** 

/s/ Lisa A. Kraeutler, Attorney-in-Fact

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Number of shares held by Domain Associates, LLC as of the date of the filing of this Form 3.
- The Reporting Person is a Managing Member of Domain Associates, LLC. Pursuant to Instruction (5)(b)(iv) of Form 3, the Reporting
- (2) Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2